mRNA Vaccine Platform for SARS-CoV2 and Other Viruses

Our vaccine design is based on the conventional non-replicating mRNA platform which carries a precedence of FDA approval. In mice, two doses of the developed mRNA vaccine candidate induced anti-Spike antibodies. These antibodies were found to be more than 90% efficient in neutralizing the infection causing interaction of SARS-CoV2 with the cognate human ACE2 receptor. To test the efficacy of the mRNA vaccine candidate, we conducted preclinical studies involving live challenge experiments in hamsters. Results shows that compared to controls, hamsters inoculated with two doses of the CCMB's mRNA vaccine candidate were substantially protected from live SARs-CoV-2 virus infection.

Indigenous mRNA vaccine against COVID-19. 

• Indigenous mRNA vaccine against COVID-19.
• offers major advantages such as easier expression of proteins than DNA based expression and is highly immunogenic.
• Due to RNA’s labile nature, the modification induced by RNA vaccine is temporary and it causes no permanent modification in host’s genome, transcriptome or proteome.
• Enhancing the stability of mRNA, which has been its handicap, was overcome by modified nucleotides and the other major innovation is in using ionizable lipids that generate well protected mRNA and are safe to humans.